ANGN
Angion Biomedica Corp
About ANGN
Angion Biomedica Corp. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company’s products include ANG-3070, ROCK2 Inhibitor, CYP11B2 Inhibitor and ANG-3777. ANG-3070 is a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung. The Company provides ANG-3070 for Fibrotic Diseases; ANG-3070 for Renal Fibrosis; ANG-3070 for Pulmonary Fibrosis. ROCK2 Inhibitor program targeted towards the treatment of fibrotic diseases. CYP11B2 Inhibitor program targeted towards diseases related to aldosterone synthase dysregulation. ANG-3777 is designed to mimic the biological activity of HGF and to treat acute organ injuries, such as delayed graft function.
Buy US stocks in Australia starting with ANGN. Open an account and start investing today!
$19.28M
-
0.00%
31.25K
$0.70
$0.64
$0.64
$2.94
$0.59
ANGN FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ANGN
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.